<DOC>
	<DOCNO>NCT02674347</DOCNO>
	<brief_summary>Study evaluate safety tolerability multiple escalating dos intravenous ( IV ) Zidebactam healthy adult human subject .</brief_summary>
	<brief_title>MAD Study Evaluate Safety , Tolerability Pharmacokinetics Intravenous Zidebactam Healthy Adults</brief_title>
	<detailed_description>A double-blind , placebo-controlled study healthy adult subject randomly assign receive either investigational product ( Zidebactam placebo ) 2 multiple ascend dose ( MAD ) cohort . Primary Objective : evaluate safety tolerability multiple escalating dos intravenous ( IV ) zidebactam healthy adult human subject . Secondary Objective : evaluate pharmacokinetics ( PK ) multiple escalate dos IV zidebactam healthy adult human subject .</detailed_description>
	<criteria>1 . Have body mass index 18 30 kg/m2 ( inclusive ) calculate weight ( kg ) /height ( m2 ) . 2 . Medical history without major pathology/surgery last 6 month prior screen . 3 . All value hematology , serum chemistry , coagulation , urinalysis show clinically significant deviation normal judge Principal Investigator . 4 . Resting supine blood pressure 90 139 ( systolic ) /40 89 ( diastolic ) mmHg rest pulse rate 40 100 beat per minute . 5 . Calculated creatinine clearance ≥80 mL/min ( CockcroftGault method ) . 6 . Computerized 12lead ECG record without sign clinically significant pathology show clinically significant deviation judge Principal Investigator . 1 . History clinically significant food drug allergy , include know hypersensitivity β lactam drug related drug . 2 . History Clostridium difficile induce diarrhea infection within 1 year screen 3 . Consumed 28 unit alcohol per week time 6 month investigational product administration 4 . History/evidence clinically relevant pathology relate cardiovascular system , central nervous system , respiratory tract , gastrointestinal tract , endocrinology , immunology , hematology systemic disorder/major surgery , opinion Principal Investigator would confound subject 's participation followup study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>